ORTX Orchard Therapeutics plc ADRs

Orchard Therapeutics plc, an integrated biopharmaceutical company, focuses on developing various transformative treatments. It dedicated to transform the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. Its commercial stage products include Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company, formerly known as Orchard Rx Limited, was founded in 2015 and is headquartered in London, the United Kingdom. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$4.89  +0.19 (4.04%)
As of 06/18/2021 15:59:43 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  
IPO date:  10/31/2018
Outstanding shares:  123,769,373
Average volume:  469,119
Market cap:   $581,716,053
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    68570P101
ISIN:        US68570P1012
Sedol:      BGT3960
Valuation   (See tab for details)
PE ratio:   -8.84
PB ratio:   2.03
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy